Biomarkers Consortium Programs

The identification of new biomarkers is an increasingly essential element of predictive, preventive and personalized medicine. To meet this need, The Biomarkers Consortium projects serve to develop promising biomarkers in order to help accelerate the delivery of successful new technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease.

Phase II trial of novel investigative breast cancer agents in the neoadjuvant setting that uses biomarkers and adaptive design to accelerate the clinical trial process.
Finding effective treatments for neurodegenerative diseases and psychiatric disorders using inflammatory biomarkers
Minimal residual disease (MRD) is the amount of disease detected by molecular or cellular means when the patient is in a clinical and pathological state of remission after treatment of leukemia. The goals of this project are to assess whether MRD may be an endpoint for use as a DDT and to standardize MRD measurement in adult precursor B-lineage ALL.
Fostering the development of better ulcerative colitis treatments by improving researchers’ ability to measure mucosal healing
Developing tools to identify treatments for some of the deadliest cancers  
Transforming drug development for osteoarthritis by discovering innovative biomarkers for use in osteoarthritis clinical trials